logo

Abbvie (ABBV)



Trade ABBV now with
  Date
  Headline
6/19/2018 9:23:04 AM AbbVie Teams Up With Leading Nonprofits To Launch Its Fifth Annual Week Of Possibilities Global Volunteering Program
6/15/2018 2:47:19 AM AbbVie Announces New Undetectable Minimal Residual Disease Data From Phase 3 MURANO Trial Of Venetoclax With Rituximab
6/14/2018 6:55:28 PM AbbVie (ABBV) Declares Quarterly Dividend of $ 0.96, Record Date 7/13/2018
6/5/2018 8:33:12 AM AbbVie: Upadacitinib Monotherapy Meets All Primary And Ranked Secondary Endpoints Versus Methotrexate In Phase 3 Study
6/4/2018 8:08:20 AM AbbVie Announces Final Results Of Modified Dutch Auction Tender Offer
6/3/2018 11:13:43 AM AbbVie:Phase2 IMBRUVICA Plus VENCLEXTA Early Data Show High Rates Of Responses In Patients With Previously-Untreated CLL
5/24/2018 9:06:02 AM AbbVie Says Phase 3 ILLUMINATE Trial Met Primary Endpoint Of Improvement In Progression-free Survival
5/1/2018 8:51:02 AM AbbVie Submits MAA To EMA For Investigational Treatment Risankizumab For Moderate To Severe Plaque Psoriasis
5/1/2018 7:48:20 AM AbbVie Commences Self-Tender Offer For Up To $7.5 Bln Of Common Stock
4/27/2018 8:06:52 AM AbbVie Presents New Investigational Data For Elagolix At 2018 ACOG Annual Meeting
4/26/2018 7:47:48 AM AbbVie Reports Q1 EPS Of $1.74 On A GAAP Basis; Adj. EPS Of $1.87
4/25/2018 8:46:59 AM AbbVie Submits BLA To FDA For Investigational Treatment Risankizumab For Moderate To Severe Plaque Psoriasis
4/25/2018 8:35:40 AM AbbVie: Upadacitinib Meets Primary, Key Efficacy Endpoints In Phase 2b/3 Rheumatoid Arthritis Study In Japanese Patients
4/10/2018 8:17:25 AM AbbVie And Neurocrine Biosciences Announce PDUFA Target Date Of Q3 2018 For Elagolix In Endometriosis-Associated Pain